In recent years, the emergence of immune checkpoint inhibitors (ICIs), particularly those targeting the programmed cell death protein‐1 (PD‐1) or its ligand PD‐L1, has revolutionized the treatment landscape of NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.